Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_assertion type Assertion NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_head.
- NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_assertion wasGeneratedBy ECO_0000203 NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_provenance.
- NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_assertion wasDerivedFrom befree-20140225 NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_provenance.
- NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_assertion SIO_000772 21747904 NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_provenance.
- NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_assertion evidence source_evidence_literature NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_provenance.
- NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_assertion description "[Thus, the presence of ESO Ab identifies a tumor subtype of HR⁻ (HER2⁻ or HER2⁺) primary BC with frequent ESO expression and, together with the assessment of antigen expression in the tumor, may be instrumental for the selection of patients for whom ESO-based immunotherapy may complement standard therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP935068.RAp3GFZ0obMV_kxM9km3RfkVAkRPJqGj9l-Q0XHg9V01k130_provenance.